These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32811736)

  • 1. Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.
    Mannucci E; Monami M; Candido R; Pintaudi B; Targher G;
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1601-1608. PubMed ID: 32811736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):699-704. PubMed ID: 33549430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Mannucci E; Targher G; Nreu B; Pintaudi B; Candido R; Giaccari A; Gallo M; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Jun; 32(6):1353-1360. PubMed ID: 35422359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Mannucci E; Giaccari A; Gallo M; Targher G; Pintaudi B; Candido R; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Mar; 32(3):529-536. PubMed ID: 35144855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
    Mannucci E; Gallo M; Giaccari A; Candido R; Pintaudi B; Targher G; Monami M;
    Diabetes Obes Metab; 2023 Feb; 25(2):444-453. PubMed ID: 36205446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK; Yeh JI
    Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials.
    Mannucci E; Naletto L; Vaccaro G; Silverii A; Dicembrini I; Pintaudi B; Monami M
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1027-1034. PubMed ID: 33618919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.
    Mannucci E; Gallo M; Pintaudi B; Targher G; Candido R; Giaccari A; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):511-514. PubMed ID: 34893404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Monami M; Dicembrini I; Mannucci E
    Acta Diabetol; 2017 Jan; 54(1):19-36. PubMed ID: 27488726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
    Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
    Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
    Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
    Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.
    Zhuang XD; He X; Yang DY; Guo Y; He JG; Xiao HP; Liao XX
    Cardiovasc Diabetol; 2018 Jun; 17(1):79. PubMed ID: 29871636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.